Table 1.
Demographic and immunological characteristics of the measles vaccine and rubella vaccine study subjects
| Measles vaccine study (N=764) | Rubella vaccine study (N=1,052) | |
|---|---|---|
| Gender | ||
| Male | 427 (55.9 %) | 578 (54.9 %) |
| Female | 337 (44.1 %) | 474 (45.1 %) |
| Race | ||
| American-Indian, Alaska Native | 2 (0.3%) | 4 (0.4%) |
| Asian, Hawaiian, Pacific Islander | 20 (2.6 %) | 27 (2.6 %) |
| Black or African American | 89 (11.6 %) | 86 (8.2 %) |
| Caucasian-American | 616 (80.6 %) | 893 (84.9 %) |
| Multiple | 23 (3.0 %) | 28 (2.7 %) |
| Other | 8 (1.0 %) | 8 (0.8 %) |
| Unknown | 6 (0.8 %) | 6 (0.6 %) |
| Ethnicity | ||
| Not Hispanic or Latino | 742 (97.1 %) | 1,025 (97.4 %) |
| Hispanic or Latino | 15 (2.0 %) | 20 (1.9 %) |
| Don't Know | 7 (0.9 %) | 7 (0.7 %) |
| Age at first vaccination (months) | ||
| N | 764 | 1,052 |
| Mean (SD) | 21.5 (24.7) | 20.2 (21.2) |
| Median | 15.0 | 15.0 |
| Q1, Q3 | 15.0, 16.0 | 15.0, 16.0 |
| Range | (11.0-181.0) | (11.0-185.0) |
| Age at second vaccination (years) | ||
| N | 764 | 1,052 |
| Mean (SD) | 7.3 (3.3) | 8.4 (3.5) |
| Median | 5.0 | 9.0 |
| Q1, Q3 | 4.0, 11.0 | 5.0, 12.0 |
| Range | (1.0-15.0) | (1.0-17.0) |
| Time from second vaccination to enrollment (years) | ||
| N | 764 | 1,052 |
| Mean (SD) | 7.5 (2.7) | 6.7 (2.9) |
| Median | 7.4 | 6.4 |
| Q1, Q3 | 5.6, 9.2 | 4.6, 8.6 |
| Range | (0.4-16.8) | (0.4-16.8) |
| Immune measure | ||
| Neutralizing antibody (NT50) | ||
| N | 763 | 1,042 |
| Mean (SD) | 1,263.9 (1,158.4) | 82.3 (124.5) |
| Median | 844.0 | 57.4 |
| Q1, Q3 | 418.0, 1,752.0 | 34.9, 95.8 |
| Range | (45.0-7,723.0) | (17.0-2,391.2) |
| IL-6 (ng/μl) | ||
| N | 756 | 1,001 |
| Mean (SD) | 362.5 (170.6) | 3,436.8 (906.8) |
| Median | 354.6 | 3,595.6 |
| Q1, Q3 | 248.5, 461.4 | 3,032.0, 4,008.4 |
| Range | (–163.7 to 1,053.6) | (–957.3 to 5,831.8) |
| IFNg (ng/μl) | ||
| N | 756 | 982 |
| Mean (SD) | 95.6 (97.1) | 24.3 (69.6) |
| Median | 67.4 | 6.2 |
| Q1, Q3 | 35.2, 120.5 | 1.5, 20.2 |
| Range | (–211.9 to 623.5) | (–239.0 to 579.4) |
SD standard deviation, Q1 first quartile, Q3 third quartile, NT50 neutralizing titer, IL interleukin, IFN interferon